Respiratorius AB (publ)
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was inc… Read more
Respiratorius AB (publ) (HF00) - Total Liabilities
Latest total liabilities as of September 2025: €913.00K EUR
Based on the latest financial reports, Respiratorius AB (publ) (HF00) has total liabilities worth €913.00K EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Respiratorius AB (publ) - Total Liabilities Trend (2021–2024)
This chart illustrates how Respiratorius AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Respiratorius AB (publ) Competitors by Total Liabilities
The table below lists competitors of Respiratorius AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IMPLENIA N (I8T.SG)
STU:I8T
|
Germany | €2.33 Billion |
|
GRACO (GA8.SG)
STU:GA8
|
Germany | €462.35 Million |
|
Top Systems-L
TA:TOPS
|
Israel | ILA234.43 Million |
|
PRINCIPAL FINANCIAL (PG4.SG)
STU:PG4
|
Germany | €311.26 Billion |
|
SHAREHOLD VAL BET. - Dusseldorf Stock Exchang
DU:SVE
|
Germany | €2.26 Million |
|
Heartbeam Inc. Warrant
NASDAQ:BEATW
|
USA | $1.86 Million |
|
GAS2GRID Ltd
AU:GGX
|
Australia | AU$6.96 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Respiratorius AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Respiratorius AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Respiratorius AB (publ) (2021–2024)
The table below shows the annual total liabilities of Respiratorius AB (publ) from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €920.10K | -27.42% |
| 2023-12-31 | €1.27 Million | -10.91% |
| 2022-12-31 | €1.42 Million | -72.61% |
| 2021-12-31 | €5.20 Million | -- |